Life sciences tools Laboratory Products and Biopharma Services segment income margin measures segment income as a percentage of revenue under Thermo Fisher Scientific's segment reporting framework.
Thermo Fisher reported a 14.0% segment income margin in the second quarter of 2026, compared with 13.8% a year earlier.
Productivity and acquisitions outweighed mix pressure
Thermo Fisher said the margin increase reflected strong productivity and acquisition effects, partly offset by unfavorable business mix and strategic investments.
The small margin increase therefore accompanied much faster reported revenue growth.
Revenue growth and conversion answer different questions
Organic revenue growth measures underlying top-line change after selected adjustments, while segment income margin measures profitability under the issuer's management reporting definition.
Use both segment organic revenue growth and clinical research growth contribution.
Primary source: Thermo Fisher Scientific Q2 2026 Form 10-Q.
Part of the Life Sciences Tools & Biopharma Services Economics
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
- TMOOpen operating-model research →10 of 10 reviewed concepts in Life Sciences Tools & Biopharma Services EconomicsSegment income conversion4 of 4 bridge concepts supportedContinue through this bridge:Analytical Instruments MarginLife Sciences Solutions MarginSpecialty Diagnostics Margin
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare lab products and biopharma margins
Compare segment-income conversion with productivity, acquisitions, business mix, and strategic investment context intact.
Explore more topics in the Financial Research Encyclopedia.